Marex Group’s Altimmune ALT Stock Holding History

Marex Group’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25,000	Closed	-$125K	–	655
2025 Q1	$125K	Hold	25,000	–	–	﹤0.01%	612
2024 Q4	$180K	Sell	25,000 -25,000	-50%	-$191K	﹤0.01%	566
2024 Q3	$307K	Sell	50,000 -2,000	-4%	-$13.5K	0.01%	376
2024 Q2	$346K	Buy	52,000 +22,000	+73%	+$162K	0.01%	382
2024 Q1	$305K	Buy	+30,000	New	+$305K	0.01%	326

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marex Group's ALT Position: Q2 2025 in Review

Marex Group sold out of Altimmune (ALT) in Q2 2025, closing a stake of 25,000 shares — an estimated $125K sold.

Marex Group first reported a position in ALT in Q1 2024 and held it in 5 quarters. The position peaked at $346K in Q2 2024. 180 funds tracked by Wall St. Rank hold ALT as of Q2 2025.

Marex Group reported no remaining Altimmune position as of Q2 2025 after selling out during the quarter.
Marex Group sold 25,000 Altimmune shares in Q2 2025, an estimated $125K.
Marex Group first reported a position in Altimmune in Q1 2024 and held it in 5 quarters.
Marex Group's Altimmune position peaked at $346K in Q2 2024.
180 funds tracked by Wall St. Rank held Altimmune as of Q2 2025.

Based on Marex Group's 13F filing for Q2 2025, filed 19 Aug 2025.